Skip to main content
Terug
Watch Compare

Cytosorbents Corp

Datakwaliteit: 83%
CTSO
NASDAQ Manufacturing Measuring & Analyzing Instruments
€ 0,61
▲ € 0,01 (0,84%)
Marktkapitalisatie: 38,31 M
Prijs
€ 0,61
Marktkapitalisatie
38,31 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -12,54 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-79,57%
Onder sectorgemiddelde (-54,01%)
ROIC-31,58%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
1,61
Boven sectorgemiddelde (0,30)
Current Ratio2,11
Interest CoverageN/A

Waardering

PE (TTM)
-4,67
Onder sectorgemiddelde (-1,49)
P/B Ratio4,25
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -4,7 -1,5
P/B 4,3 1,6
ROE % -79,6 -54,0
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E 1,6 0,3

Koersdoel Analisten

3 analisten
Buy
Huidig
€ 0,61
+760.7%
Koersdoel
€ 5,25
€ 0,75
€ 5,00
€ 10,00
Vooruitzicht
Forward WPA € 0,00
Omzet Sch. 49,08 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 € 0,00
€ 0,00 – € 0,00
 49,08 M 1
FY2026 -€ 0,18
-€ 0,19 – -€ 0,16
 40,09 M 3

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,05 -€ 0,09 -80,0%
Q32025 -€ 0,05 -€ 0,05 -7,1%
Q22025 -€ 0,06 € 0,03 +152,9%
Q12025 -€ 0,07 -€ 0,02 +71,4%

ETFs Holding This Stock

CFSSX CFSSX
0,00% weight
CFSLX CFSLX
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -8,20 M
ROE -79,57% ROA -17,49%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -12,54 M
ROIC -31,58% FCF Growth (3Y) N/A
Safety
Debt / Equity 1,61 Current Ratio 2,11
Interest Coverage N/A Asset Turnover N/A
Working Capital 11,20 M Tangible Book Value 5,43 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4,67 Forward P/E N/A
P/B Ratio 4,25 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 0,78 Fwd Earnings Yield N/A
FCF Yield -32,74%
Market Cap 38,31 M Enterprise Value 45,34 M
Per Share
EPS (Diluted TTM) -0,13 Revenue / Share N/A
FCF / Share -0,20 OCF / Share -0,20
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 152,98%
SBC-Adj. FCF -15,20 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -8,20 M -20,72 M -28,51 M -32,81 M -24,56 M
EPS (Diluted) -0,13 -0,38 -0,64 -0,75 -0,57
Gross Profit 26,49 M 25,13 M 22,39 M 20,73 M 32,12 M
Operating Income -14,75 M -16,79 M -31,21 M -31,52 M -22,74 M
EBITDA — — — — —
R&D Expenses — — 15,73 M 15,12 M 16,38 M
SG&A Expenses 35,65 M 35,00 M 33,60 M 34,29 M 35,75 M
D&A 1,23 M 1,57 M 1,46 M 882.621,0 731.578,0
Interest Expense — — — — —
Income Tax -401.000,0 -1,69 M -813.739,0 -1,09 M -736.003,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 44,18 M 47,37 M 53,26 M 63,23 M 89,52 M
Total Liabilities 38,28 M 36,26 M 29,99 M 27,86 M 26,94 M
Shareholders' Equity 5,90 M 11,11 M 23,28 M 35,37 M 62,58 M
Total Debt 16,67 M 14,00 M 5,04 M 5,00 M —
Cash & Equivalents 6,25 M 3,28 M 14,13 M 22,14 M 52,14 M
Current Assets 20,63 M 21,60 M 25,70 M 33,76 M 64,30 M
Current Liabilities 9,71 M 9,82 M 14,55 M 9,71 M 13,69 M